Generic Product New (August 2020)

Pharmacy Times, August 2020, Volume 88, Issue 8

Generic products featured in the August 2020 issue of Pharmacy TimesTM.

: Dr. Reddy’s Laboratories

COMPARE TO: Colcrys

Indicated to prevent and treat gout attacks, Dr. Reddy’s Laboratories colchicine tablets are available in a dose strength of 0.6 mg in 30- and 100-count bottles. Colchicine tablets should not be taken by patients who have kidney and liver problems, and they may cause serious adverse effects including infections, muscle weakness or pain, and unusual bleeding or bruising. The Colcrys brand and generic had a market value of about $491 million for the 12 months ending in March 2020, according to data from IQVIA.

FOR MORE INFORMATION: drreddys.com

DIHYDROERGOTAMINE MESYLATE NASAL SPRAYMARKETED BY: Leucadia

Pharmaceuticals

COMPARE TO: Migranal Dihydroergotamine mesylate nasal spray 0.5 mg, an FDA-approved spray, is indicated for acute treatment of migraine headaches with or without aura. The drug is an ergot alkaloid that works by narrowing the blood vessels in the brain. It may cause adverse effects, such as a sore nose and throat, changes in taste, dizziness, or nausea. The drug is AB-rated, barcoded, and free of preservatives, and does not contain natural rubber latex, according to a statement. The spray is available in 3.5-mL vials.

FOR MORE INFORMATION: leucadiapharma.com

MELOXICAM CAPSULESMARKETED BY: Lupin Limited

COMPARE TO: Vivlodex

Expected to launch soon, Lupin Limited’s generic meloxicam capsules will be available in 5- and 10-mg dose strengths for patients with osteoarthritis pain. The drug is a low-dose nonsteroidal anti-inflammatory option. It can cause serious adverse effects, including an increased risk of a heart attack or stroke, which may be escalated with higher doses or longer use of the drug. Meloxicam had a market value of about $14 million in March 2020, according to data from IQVIA.

FOR MORE INFORMATION: lupin.com

EVEROLIMUS TABLETSMARKETED BY: Teva Pharmaceuticals

COMPARE TO: Afinitor

Teva Pharmaceuticals has recently launched its generic everolimus tablets, indicated to treat patients with advanced renal cell carcinoma after other treatments have failed, and renal angiomyolipoma and tuberous sclerosis complex that does not require immediate surgery. The tablets are available in dose strengths of 2.5, 5, and 7.5 mg and come in blister packs of 28 tablets.

FOR MORE INFORMATION: tevapharm.com